Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
NXGL 
Nexgel Inc (NXGL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: NXGL (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $6
1 Year Target Price $6
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -37.04% | Avg. Invested days 26 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 20.81M USD | Price to earnings Ratio - | 1Y Target Price 6 |
Price to earnings Ratio - | 1Y Target Price 6 | ||
Volume (30-day avg) 1 | Beta 0.57 | 52 Weeks Range 2.10 - 5.10 | Updated Date 10/15/2025 |
52 Weeks Range 2.10 - 5.10 | Updated Date 10/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.4 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -25.02% | Operating Margin (TTM) -22.05% |
Management Effectiveness
Return on Assets (TTM) -19.51% | Return on Equity (TTM) -60.47% |
Valuation
Trailing PE - | Forward PE 15.2 | Enterprise Value 21537446 | Price to Sales(TTM) 1.78 |
Enterprise Value 21537446 | Price to Sales(TTM) 1.78 | ||
Enterprise Value to Revenue 1.85 | Enterprise Value to EBITDA -0.85 | Shares Outstanding 8067580 | Shares Floating 6836306 |
Shares Outstanding 8067580 | Shares Floating 6836306 | ||
Percent Insiders 15.26 | Percent Institutions 8.94 |
Upturn AI SWOT
Nexgel Inc
Company Overview
History and Background
Nexgel Inc. is a hydrogel technology company developing, manufacturing, and commercializing high water content, cross-linked polymer hydrogels for wound care, skin care, and cosmetic applications. Founded in 2013, Nexgel aims to provide solutions that enhance comfort, reduce pain, and accelerate healing.
Core Business Areas
- Wound Care: Nexgel develops and markets hydrogel dressings for various types of wounds, including burns, surgical wounds, and pressure ulcers.
- Skin Care: The company's hydrogel technology is also used in skincare products to provide hydration, soothe irritation, and promote skin health.
- Cosmetic Applications: Nexgel's hydrogels are incorporated into cosmetic products to enhance moisturization, improve texture, and deliver active ingredients.
Leadership and Structure
Adam L. Levy is the Chairman & Chief Executive Officer. The organizational structure includes departments for research and development, manufacturing, sales and marketing, and finance and operations.
Top Products and Market Share
Key Offerings
- Advanced Wound Care Dressings: Nexgel produces a range of hydrogel dressings with varying sizes and shapes, suitable for different wound types. Limited Market Share is reported. Competitors include Smith & Nephew, Mu00f6lnlycke Health Care, and Convatec Group.
- Hydra-Lock Moisturizing Gels: Nexgel offers skincare gels formulated with its hydrogel technology to provide intense hydration and soothing benefits. Limited Market Share is reported. Competitors include Neutrogena, L'Oru00e9al, and Unilever.
Market Dynamics
Industry Overview
The advanced wound care market is growing due to the aging population, increasing incidence of chronic diseases like diabetes, and rising awareness of advanced wound care products. The skincare market is also expanding, driven by consumer demand for effective and innovative skincare solutions.
Positioning
Nexgel is positioned as a technology innovator in hydrogel-based products for wound care and skincare. Its competitive advantage lies in its proprietary hydrogel technology, which offers superior hydration, comfort, and therapeutic benefits.
Total Addressable Market (TAM)
The TAM for advanced wound care and skincare products is estimated at over $20 billion. Nexgel is positioned to capture a share of this market with its innovative products and technology.
Upturn SWOT Analysis
Strengths
- Proprietary Hydrogel Technology
- Innovative Product Development
- Strong Focus on R&D
- Potential for Product Diversification
Weaknesses
- Limited Brand Recognition
- Small Market Share
- Dependence on Key Suppliers
- Limited Financial Resources
Opportunities
- Expanding into New Geographies
- Developing Partnerships with Major Healthcare Providers
- Launching New Products for Specific Indications
- Acquiring Complementary Technologies or Businesses
Threats
- Competition from Established Players
- Regulatory Changes
- Economic Downturn
- Patent Infringement
Competitors and Market Share
Key Competitors
- Smith & Nephew (SNN)
- Mu00f6lnlycke Health Care (Private)
- Convatec Group (CTEC.L)
Competitive Landscape
Nexgel faces intense competition from larger, more established players with greater financial resources and brand recognition. Nexgel's competitive advantage lies in its hydrogel technology, but it must overcome its smaller scale and limited market presence.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited due to the company's stage and lack of profitability.
Future Projections: Future projections are speculative and depend on the company's ability to commercialize its products and secure funding.
Recent Initiatives: Recent initiatives include expanding its sales and marketing efforts and developing new products for specific markets.
Summary
Nexgel Inc. is an early-stage company with innovative hydrogel technology, but it faces challenges related to limited market share, competition, and financial resources. Its technology offers potential for growth in the wound care and skincare markets. The company needs to focus on commercializing its products and securing additional funding. Nexgel will have to demonstrate more market leadership to justify its current valuation.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- Public Filings
- Market Research Reports
Disclaimers:
The information provided is for informational purposes only and should not be construed as investment advice. Market share data is based on estimates and may not be precise. Financial data may be outdated or incomplete due to the company's size and reporting requirements.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Nexgel Inc
Exchange NASDAQ | Headquaters Langhorne, PA, United States | ||
IPO Launch date 2021-12-22 | CEO, President & Director Mr. Adam R. Levy | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 19 | Website https://nexgel.com |
Full time employees 19 | Website https://nexgel.com | ||
NEXGEL, Inc. manufactures and sells high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels for wound care, medical diagnostics, transdermal drug delivery, and cosmetics in the United States. It operates through two segments: Nexgel and CG labs. The company offers over-the-counter remedy solutions, such as blister and pain applications; and beauty and cosmetic solutions. It also developing NEXDrape, an incise surgical drape designed for patients with impaired skin; and NEXDerm, an adhesive tape designed to secure central lines and intravenous tubes and devices to patients before, during, and after medical treatment. In addition, the company engages in the converting and packaging business. It serves its customers under Medagel, Lumagel Beauty, Kenkoderm and Silly George brand names. The company was formerly known as AquaMed Technologies, Inc. and changed its name to NEXGEL, Inc. in November 2019. NEXGEL, Inc. was incorporated in 2009 and is based in Langhorne, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.